OCWP
KROS icon

Owl Creek Wealth Partners’s Keros Therapeutics KROS Stock Holding History

Owl Creek Wealth Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07K Hold
100
– – ﹤0.01% 1203
2026
Q1 		$1.1K Buy
+100
New +$1.54K ﹤0.01% 1155

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Owl Creek Wealth Partners's KROS Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Keros Therapeutics (KROS) position steady in Q2 2026 at 100 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1203.

Owl Creek Wealth Partners first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.1K in Q1 2026. 122 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Owl Creek Wealth Partners held 100 shares of Keros Therapeutics worth $1.07K as of Q2 2026.
  • Owl Creek Wealth Partners left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1203 holding.
  • Owl Creek Wealth Partners first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Owl Creek Wealth Partners's Keros Therapeutics position peaked at $1.1K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.